Trial Profile
A Clinical Study to Evaluate Remdisivir in Combination with Old Rheumatoid Arthritis Drug Chloroquine in China
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2020
At a glance
- Drugs Chloroquine (Primary) ; Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 11 Mar 2020 New trial record
Most Recent Events
Trial Overview
Purpose
This clinical study will evaluate Remdisivir with the old rheumatoid arthritis (RA) drug chloroquine for the treatment of patients with coronavirus.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Sponsors Gilead Sciences
- Affiliations Gilead Sciences
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase II
- Location China
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| ChloroquinePrimary Drug |
-
|
-
|
| RemdesivirPrimary Drug | Intravenous | Infusion |
Remdisivir with chloroquine
Trial Centres
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 11 Mar 2020 | New trial record | New trial record Updated 11 Mar 2020 |
References
-
Can-Fite BioPharma. Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG